- Home
- CDTX
as 12-18-2024 2:33pm EST
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 242.5M | IPO Year: | 2015 |
| Target Price: | $32.20 | AVG Volume (30 days): | 84.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.00 - $24.99 | Next Earning Date: | 11-07-2024 |
| Revenue: | $44,653,000 | Revenue Growth: | 44.48% |
| Revenue Growth (this year): | -85% | Revenue Growth (next year): | N/A |
Latest Cidara Therapeutics Inc. News
CDTX Breaking Stock News: Dive into CDTX Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
RBC Initiates Cidara Therapeutics at Outperform, Speculative Risk, With $34 Price Target
Clinical Trials Arena
13 days ago
Cidara achieves full enrolment in influenza prevention trial
GlobeNewswire
14 days ago
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza
Zacks
15 days ago
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
MT Newswires
a month ago
Cidara Therapeutics Expects to Raise $105 Million From Private Placement
GlobeNewswire
a month ago
Cidara Therapeutics Announces $105 Million Private Placement
GlobeNewswire
a month ago
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
Associated Press Finance
a month ago
Cidara Therapeutics: Q3 Earnings Snapshot
Compare CDTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDTX Cidara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.